Melanoma Clinical Trials in Los Angeles

Showing 61-80 of 122 trials

Study in Subjects With Small Primary Choroidal Melanoma

NCT03052127

The primary objective is to assess the safety, immunogenicity and efficacy of one of three dose levels and repeat dose regimens of Light-activated AU-011 and one or two laser applications for the treatment of subjects with primary choroidal melanoma.

Uveal MelanomaOcular MelanomaChoroidal Melanoma

Aura Biosciences57 participantsStarted Feb 2017

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +10 more locations

RECRUITING< 1 mile

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

NCT03941379

The purpose of this observational research study is to follow participants who have been treated with either bel-sar or received alternate treatment (sham, standard of care therapy, etc.) while participating in a previous Aura Biosciences clinical research study to assess the long-term safety and effectiveness in these subjects. This study will collect information from procedures conducted as part of routine follow-up eye care and cancer care. Additionally, the registry will collect all adverse events, information about pregnancy and symptomatic overdose.

Choroidal MelanomaIndeterminate Lesions of Eye

Aura Biosciences500 participantsStarted Mar 2019

Tucson, Arizona, United States • Los Angeles, California, United States • Palo Alto, California, United States +13 more locations

Study in Subjects With Small Primary Choroidal Melanoma

A Registry of Subjects With Primary Indeterminate Lesions or Choroidal Melanoma

Melanoma Trials in Other Cities

Safety Study of SEA-CD40 in Cancer Patients

A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors

Study of Denileukin Diftitox in Participants With Stage IIIC and Stage IV Melanoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Safety Study of MGA271 in Refractory Cancer

A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies

Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer

A Study Using Tumor-Reactive Autologous Tumor Infiltrating Lymphocytes (TIL) in Metastatic Melanomas

Study of the CD40 Agonistic Monoclonal Antibody APX005M

A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

Percutaneous Hepatic Perfusion in Patients With Hepatic-dominant Ocular Melanoma

Vaccine Therapy Using Melanoma Peptides for Cytotoxic T Cells and Helper T Cells in Treating Patients With Metastatic Melanoma

Phase I/II Study of PDR001 in Patients With Advanced Malignancies

PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma

Prospective Group-Matched Study With Belzupacap Sarotalocan (Bel-sar; AU-011) or Plaque Radiotherapy for Primary Indeterminate Lesions or Choroidal Melanoma (IL/ CM)

Study of A166 in Patients With Relapsed/Refractory Cancers Expressing HER2 Antigen or Having Amplified HER2 Gene

Other Conditions in Los Angeles